Elevated plasma levels of limulus amoebocyte lysate-reactive material [1]

Journal of Infectious Diseases

Volumn 194, Issue 9, 2006, Pages 1340-

  Rossignol, Daniel ^a   Lynn, Melvyn ^a   Wittek, Alec ^a   Rose, Jeffrey ^b  

^a EISAI INC   (United States)

^b EISAI RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E 5564; ENDOTOXIN; ERITORAN; LIPID A DERIVATIVE; UNCLASSIFIED DRUG;

DRUG BLOOD LEVEL; LETTER; LIMULUS LYSATE TEST; NONHUMAN; PRIORITY JOURNAL; TOXIN ANALYSIS;

EID: 33750295378     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/508223     Document Type: Letter

References (2)

1. Solomon SB, Cui X, Gerstenberger E, et al. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J Infect Dis 2006; 193:634-44.
2. Mullarkey M, Rose JR, Bristol J, et al. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304:1093-102.